tradmap

SUPN Earnings Supernus Pharmaceuticals, Inc.

Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Latest filing

Annual results

Diluted EPS (annual)
-$1 $1 $2 $0 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
EPS
Revenue (annual)
$0 $359M $719M 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Revenue
Net income (annual)
-$39M $44M $127M $0 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Net income

Quarterly results

Diluted EPS (quarterly)
-$1 -$0 $1 $0 Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25 Q2 '26
EPS
Revenue (quarterly)
$0 $113M $227M Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25 Q2 '26
Revenue
Net income (quarterly)
-$58M -$10M $38M $0 Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25 Q2 '26
Net income

Reported EPS history

1–60 of 60
Q3 20262026-09-300.352026-10-2910-Q
Q2 20262026-06-30-1.012026-08-0310-Q
Q1 20262026-03-31-0.042026-05-0510-Q
Q4 2025 (derived)2025-12-31-0.072026-03-0210-K
FY 20252025-12-31-0.682026-03-0210-K
Q3 20252025-09-30-0.802025-11-0610-Q
Q2 20252025-06-300.402025-08-0510-Q
Q1 20252025-03-31-0.212025-05-0610-Q
Q4 2024 (derived)2024-12-310.272025-02-2510-K
FY 20242024-12-311.322025-02-2510-K
Q3 20242024-09-300.692024-11-0410-Q
Q2 20242024-06-300.362024-08-0610-Q
Q1 20242024-03-310.002024-05-0810-Q
Q4 2023 (derived)2023-12-310.04——
FY 20232023-12-310.02——
Q3 20232023-09-30-0.292023-11-0810-Q
Q2 20232023-06-30-0.022023-08-0810-Q
Q1 20232023-03-310.292023-05-0910-Q
Q4 2022 (derived)2022-12-310.442023-03-0910-K
FY 20222022-12-311.042023-03-0910-K
Q3 20222022-09-300.032022-11-0910-Q
Q2 20222022-06-300.142022-08-0810-Q
Q1 20222022-03-310.432022-05-1210-Q
Q4 2021 (derived)2021-12-310.042022-04-1310-K
FY 20212021-12-310.982022-04-1310-K
Q3 20212021-09-300.402021-11-0510-Q
Q2 20212021-06-300.432021-08-0610-Q
Q1 20212021-03-310.112021-05-0710-Q
Q4 2020 (derived)2020-12-310.572021-03-0810-K
FY 20202020-12-312.362021-03-0810-K
Q3 20202020-09-300.742020-11-0610-Q
Q2 20202020-06-300.652020-08-1710-Q
Q1 20202020-03-310.402020-05-1510-Q
Q4 20192019-12-310.622020-02-2810-K
FY 20192019-12-312.102020-02-2810-K
Q3 20192019-09-300.542019-11-0810-Q
Q2 20192019-06-300.612019-08-0910-Q
Q1 20192019-03-310.342019-05-1010-Q
Q4 20182018-12-310.482019-03-0110-K
FY 20182018-12-312.052019-03-0110-K
Q3 20182018-09-300.522018-11-0910-Q
Q2 20182018-06-300.572018-08-0910-Q
Q1 20182018-03-310.492018-05-1010-Q
Q4 20172017-12-310.262018-03-0110-K
FY 20172017-12-311.082018-03-0110-K
Q3 20172017-09-300.292017-11-0910-Q
Q2 20172017-06-300.322017-08-0310-Q
Q1 20172017-03-310.192017-05-0910-Q
Q4 20162016-12-310.262017-03-1610-K
FY 20162016-12-311.762017-03-1610-K
Q3 20162016-09-301.182017-01-2010-Q
Q2 20162016-06-300.182016-08-0510-Q
Q1 20162016-03-310.082016-05-1010-Q
Q4 20152015-12-310.142016-03-0910-K
FY 20152015-12-310.282016-03-0910-K
Q3 20152015-09-300.082015-11-0910-Q
Q2 20152015-06-300.042015-08-0710-Q
Q1 20152015-03-310.022015-05-0610-Q
Q4 20142014-12-310.102015-03-1210-K
FY 20142014-12-31-0.262015-03-1210-K

Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Q4 EPS marked "derived" is computed as the fiscal-year EPS minus Q1–Q3 (10-Ks report only the annual figure); EPS is not strictly additive across quarters, so it can differ by a cent or two from the issuer's own Q4. A period with no "Reported" date is known only from a later filing's prior-year comparative. Informational only — not financial advice.